Toxicity of targeted anticancer treatments on the liver in myeloproliferative neoplasms

Abstract

The liver has a central role in metabolism, therefore, it is susceptible to harmful effects of ingested medications (drugs, herbs, and nutritional supplements). Drug-induced liver injury (DILI) comprises a range of unexpected reactions that occur after exposure to various classes of medication. Even though most cases consist of mild, temporary elevations in liver enzyme markers, DILI can also manifest as acute liver failure in some patients and can be associated with mortality. Herein, we briefly review available data on DILI induced by targeted anticancer agents in managing classical myeloproliferative neoplasms: Chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, and myelofibrosis.

Keywords: Chronic myeloid leukemia; Drug-induced liver injury; Essential thrombocythemia; Hepatotoxicity; Myelofibrosis; Myeloproliferative neoplasms; Polycythemia vera.